Ok, update... labels are in, raws and carriers are in, just need to get the stupid credit card processing stuff done and we will be ready to roll.
The sublingual PCT... Ok, here is the deal with it:
The problem I feel with natural SERMS is that they are not particularily bioavailable. For example Resveratrol is a good SERM/ERM but is rapidly sulfated. Some people put in Quercetin and then take massive doses, but I think this isn't necessarily the best choice. I feel that Ellagic Acid has a similar problem in the cut, due to its similar structure.
Both are good SERMs (I will post the study on Ellagic Acid at the end of this post) but suffer from a lack of bioavailability.
Additionally, if you look at tamoxifen, it uses a similar liver blocking system to keep it active, which is why it is not really the best for PCT after a cycle of orals.
So, an oral product would have to stay around for a long while in order to work properly. A sublingual product dosed 3 times per day I think solves all of these issues.
Direct liver passing effect.
Direct stomach passing effect means no sulfotransferase issues.
Low molecular weights of both Ellagic Acid and Resveratrol makes it feasable.
So, in a nutshell, that is the basis for the product. Just running it now.
Evaluation of estrogenic/antiestrogenic activity of ellagic acid via the estrogen receptor subtypes ERalpha and ERbeta.Papoutsi Z, Kassi E, Tsiapara A, Fokialakis N, Chrousos GP, Moutsatsou P.
Department of Biological Chemistry, Medical School, University of Athens Mikras Asias Str 75, Goudi, Athens 11527, Greece.
Ellagic acid is a plant-derived polyphenol, possessing antioxidant, antiproliferative, and antiatherogenic properties. Whether this compound has estrogenic/antiestrogenic activity, however, remains largely unknown. To answer this question, we first investigated the ability of ellagic acid to influence the activity of the estrogen receptor subtypes ERalpha and ERbeta in HeLa cells. Cells co-transfected with an estrogen response element (ERE)-driven luciferase (Luc) reporter gene and an ERalpha- or ERbeta-expression vector were exposed to graded concentrations of ellagic acid. At low concentrations (10(-7) to 10(-9) M), this compound displayed a small but significant estrogenic activity via ERalpha, whereas it was a complete estrogen antagonist via ERbeta. Further evaluation revealed that ellagic acid was a potent antiestrogen in MCF-7 breast cancer-derived cells, increasing, like the pure estrogen antagonist ICI182780, IGFBP-3 levels. Moreover, ellagic acid induced nodule mineralization in an osteoblastic cell line (KS483), an effect that was abolished by the estrogen antagonist. Endometrium-derived epithelial cells (Ishikawa) showed no response to the natural compound by using a cell viability assay (MTT). These findings suggest that ellagic acid may be a natural selective estrogen receptor modulator (SERM).